Marit Renée Myhre

  • Research associate PhD
  • +47 22 78 23 18

Education:

2004 – 2010: PhD in Virology (Faculty of Health Sciences, University of Tromsø, Norway)
“A study of the Human Polyomavirus BK Replication and the Role of its Agnoprotein”

1997 – 1999: MSc in Microbiology (Department of Medical Microbiology, University of Tromsø, Norway) “Vancomycin-Resistand Enterococci”

1993 – 1997:  BSc in Biology (University of Tromsø, Norway)

 

Research interests/projects:

Pre-clinical study, analysis, and validation of immune treatments mechanisms and effects, as well as in-vivo modelling and verification of novel cell-based therapies

    • Therapeutic TCR discovery and pre-clinical validation
    • Chimeric Antigen Receptors (CAR) discovery and pre-clinical validation
    • Discovery and pre-clinical validation of vaccination targets
    • Development of novel technologies to improve cell-based therapy

Work experience

2013 – present: Research Fellow, Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway

2009 – 2013:   Research Fellow, Dept. of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway

1999 – 2004:   Research assistant, Department of Medical Microbiology, University of Tromsø, Norway

 

 

 

Publications 2019

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Publications 2018

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Publications 2015

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098

Publications 2009

Myhre MR, Olsen GH, Gosert R, Hirsch HH, Rinaldo CH (2009)
Clinical polyomavirus BK variants with agnogene deletion are non-functional but rescued by trans-complementation
Virology, 398 (1), 12-20
DOI 10.1016/j.virol.2009.11.029, PubMed 20005552

Publications 2008

Johannessen M, Myhre MR, Dragset M, Tümmler C, Moens U (2008)
Phosphorylation of human polyomavirus BK agnoprotein at Ser-11 is mediated by PKC and has an important regulative function
Virology, 379 (1), 97-109
DOI 10.1016/j.virol.2008.06.007, PubMed 18635245

Publications 2003

Rinaldo CH, Myhre MR, Alstad H, Nilssen Ø, Traavik T (2003)
Human polyomavirus BK (BKV) transiently transforms and persistently infects cultured osteosarcoma cells
Virus Res, 93 (2), 181-7
DOI 10.1016/s0168-1702(03)00096-0, PubMed 12782366

Publications 2000

Simonsen GS, Myhre MR, Dahl KH, Olsvik O, Sundsfjord A (2000)
Typeability of Tn1546-like elements in vancomycin-resistant enterococci using long-range PCRs and specific analysis of polymorphic regions
Microb Drug Resist, 6 (1), 49-57
DOI 10.1089/mdr.2000.6.49, PubMed 10868807

Page visits: 2206